A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Acronyms CENTAurus
- Sponsors Novartis Pharmaceuticals
- 20 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
- 02 Jun 2014 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
- 02 Jun 2014 Planned initiation date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.